ADVANZ PHARMA

#News for #investors and #media: ADVANZ PHARMA secures rights to commercialise Alvotech’s biosimilar candidate in Europe. We are excited to reinforce our collaboration with Alvotech by adding an impactful and meaningful product to our growing pipeline. This partnership leverages our combined strengths and reinforces ADVANZ PHARMA as a partner of choice for the commercialisation of specialty pharmaceuticals in Europe. More details here: bit.ly/3KMkclO #partnerofchoice #growth #specialtypharma

We're excited to participate in the Global Steps Challenge as part of Mental Health Awareness Week. At ADVANZ PHARMA, we understand the importance of prioritising mental well-being, and we're stepping up to show our support. Throughout this week, our team members around the globe will be taking steps to raise awareness for mental health. Whether walking, running, or hiking, every step brings us closer to fostering a healthy workplace culture. #MentalHealthAwarenessWeek #StepForwardForWellness 

Our #ThisIsADVANZPHARMA series continues! Today, we're thrilled to introduce Daniel West, Vice President Business Development & Licensing, who's been with us since 2018. Daniel joined ADVANZ PHARMA with a clear mission: to support our growth as a patient-centric organisation. He explains: "Every day, I get to work on innovations that could fill unmet medical needs and make a real difference in the lives of patients. It's rewarding to play a pivotal role in bringing groundbreaking, value-added medicines to market." What keeps Daniel excited? "The passion and creativity of my colleagues and peers. We're all committed to enhancing healthcare systems, harmonising development and regulatory processes, and using technology to engage clinicians more effectively. It's this energy that makes ADVANZ PHARMA a great place to work." #ThisIsADVANZPHARMA #OneTeam #Innovation

We are excited about the very high employee engagement at ADVANZ PHARMA – as evidenced by our most recent staff survey. Thanks to all our colleagues who took the time to participate in this survey. The overwhelming response rate of 91% speaks volumes about the strong engagement within our teams. Among the survey findings, one of the standout results is the sense of pride our employees feel about being part of ADVANZ PHARMA, with 86% expressing their willingness to recommend us as a great place to work. Furthermore, we're proud of the high scores in areas such as clarity and progress toward our strategic goals, confidence in achieving our ambitions, teamwork, and collaboration, which are significantly above industry benchmarks. Here's to continued growth and success together! #EmployeeEngagement #Teamwork #SuccessStory

ADVANZ PHARMA announces the European Commission (EC) granted marketing authorisation in the European Union for a novel intravenous antibiotic. This antibiotic will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra Therapeutics in 2022. ADVANZ PHARMA is committed to improving patients’ lives by providing potent therapeutic options in Europe in areas with high patient need. Read more: bit.ly/3IUMwl1 #pharmaceuticals #partnerofchoice #patients 

ADVANZ PHARMA is proud to support and recognise Rare Disease Day, a globally coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for patients living with a rare disease. Collectively, it aims to change and improve the lives of millions worldwide. Rare Disease Day is observed every year on 28 February (or 29 in leap years)—the rarest day of the year. ADVANZ PHARMA is committed to advancing education and treating patients with rare conditions such as Primary Biliary Cholangitis (PBC), Acromegaly, as well as Galactosemia and Sorbitol dehydrogenase (SORD) deficiency, and improving patients’ lives by providing the rare disease medicines they depend on. #rarediseaseday2024 #raredisease #awareness #healthcare #pharmaceuticals 

ADVANZ PHARMA has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which recommended granting marketing authorisation for a novel intravenous antibiotic. ADVANZ PHARMA will commercialise the medicine across Europe once approved and continues the journey to strengthen its portfolio of innovative medicines in areas with high patient needs. Read more: bit.ly/3u8nHOR

ADVANZ PHARMA supports the World Antimicrobial Awareness Week (WAAW) 2023 and is delighted to announce joining the AMR Industry Alliance. Antimicrobial resistance (AMR) is a rising global threat, claiming lives worldwide due to the rapid emergence of resistant strains. The widespread use of antibiotics exacerbates this trend and puts future treatment options at risk. In our ongoing battle against AMR, we are pleased to announce our partnership with the AMR Industry Alliance. As a member of this global coalition, we are proud to contribute to facilitating sustainable change and promoting responsible use of antibiotics. At ADVANZ PHARMA, we are committed to improving patients’ lives by providing targeted antimicrobial treatments that help redefine practice strategies and raise the bar of clinical expectations – going beyond mere clinical improvement and instead to microbiological eradication. Ready to tackle AMR? Join the AMR Alliance’s WAAW23 events #WAAW2023 #AMRIndustryAlliance

#News for #investors and #media: ADVANZ PHARMA further expands its specialty brands portfolio by signing an agreement to acquire the global rights of a specialty medicine from Bayer. More details here: bit.ly/3Mx8L2S #partnerofchoice #growth #specialtypharma

#News for #investors and #media: ADVANZ PHARMA further strengthens its global portfolio of specialty brands with two product acquisitions, one from Kyowa Kirin International plc. and one from Bayer. More details here: bit.ly/3S41lY7 #partnerofchoice #growth #specialtypharma